Navigation Links
Platelets in Medical Technology

Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study

... was able to inhibit the aggregation of platelets even when exposed to a very potent stimulant ... stroke, which are the leading causes of death. platelets are activated at the site of atherosclerotic ... TRA binds selectively to the thrombin receptor on platelets (PAR-1), and is therefore a member of a ...

Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

... patients were increased from baseline by 20,000 platelets per microliter more than 80 percent of the time ... About Adult ITP In patients with ITP, platelets - or blood elements needed to prevent bleeding - ... when platelet counts drop to less than 30,000 platelets per microliter; normal counts range from 150,000 ...

Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients

... patients were increased from baseline by 20,000 platelets per microliter more than 80 percent of the time ... a platelet count between 50,000 and 200,000 platelets per microliter. Interim Phase 2 Nplate ... About Adult ITP In patients with ITP, platelets -- or blood cells needed to prevent bleeding -- ...

Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders

... disorders characterized by a low number of platelets in the blood, will be presented in a press ... by one of three causes: low production of platelets in the bone marrow, increased breakdown of platelets in the bloodstream, or increased breakdown ...

Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union

... About Adult ITP In patients with ITP, platelets -- or blood cells needed to prevent bleeding -- ... when platelet counts drop to less than 30,000 platelets per microliter; normal counts range from 150,000 to 400,000 platelets per microliter. ITP has historically been ...

Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting

... ITP is a disorder characterized by low levels of platelets in the blood, with patients suffering from ... PROMACTA as an oral treatment for increasing platelets in patients with chronic ITP. EXTEND is an ... for as long as patients continue to benefit and platelets remain greater than or equal to ...

Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting

... announced results of the recently completed CLEAR platelets 2 (Clopidogrel Loading with Eptifibatide ... Scientific Sessions in Orlando, FL. CLEAR platelets 2, designed to evaluate the effects of the ... and principal investigator for the CLEAR platelets 2 study. "This pharmacodynamic study supports the ...

Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned

... is an antiplatelet agent which prevents platelets from sticking together and forming clots in ... the use of antiplatelet agents to help prevent platelets from sticking together and forming clots, and ... fissure or erosion of these plaques activates platelets in the blood to form a clot (thrombus) and which ...

Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections

... while the labeled dose of linezolid produced the expected depletion of platelets and other cell lines. It is also encouraging that the efficacy of the 200 ... shifts from baseline in hematology or chemistry parameters, including platelets or liver enzymes. "The efficacy and safety of torezolid in this ...

New Research Suggests Platelet 'Stickiness' May be the Single Most Important Risk Factor in Patients Treated with Coronary Stents - Findings May be Applicable to Anyone with Vascular Disease

... know their cholesterol level, but do they know how "sticky" their platelets are? Research findings from Dr. Paul A. Gurbel, an interventional ... Along with his team at Sinai, Dr. Gurbel demonstrated that patients with platelets most prone to aggregate had the highest prevalence of complications, ...

Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial

... 5-HT2A serotonin receptor. Serotonin activation of the 5-HT2A receptor on platelets and vascular smooth muscle is thought to play an important role in events ... of the vessel wall). By blocking activation of the 5-HT2A receptor on platelets and other cardiovascular tissues, APD791 may curb these serotonin mediated ...

Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients

... remissions (CR), one patient has achieved a CRp (complete remission where platelets did not recover to greater than 100,000 platelets per microliter), and two additional patients achieved partial remissions ...

SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients

... (MI), and ischemic stroke, which are the leading causes of death. platelets are activated at the site of atherosclerotic plaque rupture in arteries ... activator of platelets. TRA binds selectively to the thrombin receptor on platelets (PAR-1), and is therefore a member of a potentially new class of drugs ...

Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation

... Department of Molecular Cardiology, investigated the mechanisms of how platelets become hyperreactive during hyperlipidemia, a condition in which there ... clinical studies and mouse models, the researchers found that CD36 on platelets modulates platelet activity in response to oxidant stress and abnormal ...

Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia

... cell death (apoptosis). In myeloproliferative disorders, mutations in JAK2 may play a role in allowing large numbers of abnormal blood cells or platelets to grow and spread in the bone marrow and the rest of the body. Based on its potential to inhibit this activity, lestaurtinib is in ongoing studies ...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... dose and pharmacokinetics of everolimus(3). The Grade 3 and 4 adverse events reported in the study included elevated bilirubin, drop in platelets count, diarrhea, bleeding, cardiac ischemia, elevated liver function tests and infection. Reactivation of Hepatitis B virus was observed in four ...

New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel

... activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking together, which can result in clogged arteries and may lead to heart attack or stroke. About Daiichi Sankyo A ...

New Study Suggests Rx Estrogen Delivery Through the Skin May Show Safety Benefits as Opposed to Oral Delivery

... therapy and whether to take it orally or through the skin." The research team studied platelet activity in the study participants' blood. platelets serve a central role in forming pathological arterial thrombosis that causes myocardial infarction and stroke. The study's authors further concluded ...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

... not appear to cause myelosuppression (depression of the immune system that may lead to life threatening infections), thrombocytopenia (a decrease in platelets that may result in bleeding), skin rash, flu-like symptoms or alopecia (hair loss); all of these toxicities occur frequently with many of the ...

CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors

... hemiparesis 6%, 18%; asthenia 6%, 13%; Adverse hematologic effects (Grade 3 to 4) in the AA trial in adults were lymphopenia (55%); platelets (19%); neutrophils (14%) and hemoglobin (4%). 7% and 9.5% of patients over age 70 experienced Grade 4 neutropenia or thrombocytopenia in the ...

FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder

... been the primary means of treating patients with ITP. Recent advances, like the clinical trials of PROMACTA, show that increasing the production of platelets may also play a significant role in treating this disorder," said James Bussel, M.D., director of the Platelet Disorders Center, Children's Cancer ...

Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders

... the only reversible, direct acting, intravenous (IV) and oral ADP receptor antagonist in clinical development. Inhibiting the P2Y12 ADP receptor on platelets has been proven to prevent thrombosis and subsequent heart attacks. Portola believes that PRT060128 may provide significant clinical benefit through ...

Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel

... activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking together, which can result in clogged arteries and may lead to heart attack or stroke. About Daiichi Sankyo Company, ...

Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel

... activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking together, which can result in clogged arteries and may lead to heart attack or stroke. About Daiichi Sankyo A global ...

Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events

... activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking together, which can result in clogged arteries and may lead to heart attack or stroke. About Daiichi Sankyo Company, ...

Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis

... on preclinical studies, promotes platelet aggregation, vasoconstriction and intimal hyperplasia. By blocking activation of the 5-HT2A receptor on platelets and other cardiovascular tissues, APD791 may curb these serotonin-mediated effects in the clinical setting, thereby reducing or preventing ....

FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel

... activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking together, which can result in clogged arteries and may lead to heart attack or stroke. About Daiichi Sankyo Company, ...

Drug-Eluting Stents Outperform Bare Stents in Heart Attack

... reasons: It is shorter-acting and is cleared from the body more readily than abciximab, it is less likely to cause a dangerous drop in the number of platelets in the blood, and it is far less expensive. However, previous studies have been too small or have used too low a dose of tirofiban to reach a ...

BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack

... unwanted blood clotting. Now a new study has found that high loading doses of clopidogrel, an oral medication that inhibits blood clots by preventing platelets from clumping together, can eliminate the need for intravenous abciximab, a standard cath-lab drug that also interferes with platelets, but through a ...

Tailored Clopidogrel Dosing Improves PCI Outcomes

... an initial, or loading, dose several times higher than usual is necessary to ensure the effectiveness of clopidogrel, a medication that prevents platelets from clumping together to form blood clots. The payoff for tailoring the clopidogrel dose: a significant reduction one month after PCI in the ...

TRITON-TIMI 38 Stent Analysis Favors Prasugrel

... dose of 60 mg of prasugrel, followed by 10 mg daily for one year. Both medications prevent unwanted blood clotting by inhibiting the ability of platelets to clump together. Stephen D. Wiviott, MD, Brigham and Women's Hospital, Boston, led the new stent analysis. Of the 12,844 patients who ultimately ...

Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel

... activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking together, which can result in clogged arteries and may lead to heart attack or stroke. Lilly, on behalf of its alliance ...

FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel

... activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking together, which can result in clogged arteries and may lead to heart attack or stroke. About Daiichi Sankyo Company, ...

BioVascular Inc. Closes $10.87 Million Series C Financing

... designed to be applied to the inner surface of the arterial wall during surgery. There, it coats exposed collagen fibrils and inhibits the binding of platelets to those fibrils. By blocking platelet adhesion, saratin blocks the first step in a sequence of events that involve platelet aggregation and ...

Lifesaving Benefits of Low-Dose Aspirin Therapy Maintained With Naproxen Sodium

... an OTC dose of naproxen sodium did not change the antiplatelet effect profile seen with aspirin therapy alone. The aggregation or accumulation of platelets can cause clotting in the arteries, which can lead to a heart attack or ischemic stroke. It has been reported that one in five Americans (an ...

Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies

... activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking together, which can result in clogged arteries and may lead to heart attack or stroke. About Daiichi Sankyo Company, ...

Surgeons Develop Innovative Life-Saving Treatments to Correct Massive Bleeding in Trauma Patients

... protocol used 7.6 units. "The big difference with TEP is you have predefined packets of blood products with larger amounts of clotting factors and platelets that the patient needs and they are ready in advance, so the surgeons don't have to worry about transfusions during a major trauma case," medical ...

Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer

... blood cell count, including a differential white cell count and platelet count. Absolute neutrophil count should be > or = 1,500 cells/mm(cubed) and platelets > or = 100,000 cells/mm(cubed). Prior to each dose, collect blood chemistry tests to evaluate renal and hepatic function. Dose adjustments ...

PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials

... hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83:193-207. (8) Gralnick HR, Vail M, McKeown LP et al. Activated platelets in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1995;91:697-702. (9) Audebert HJ, Planck J, Eisenburg M, Schrezenmeier H, Haberl RL. ...
Other Contents
(Date:7/25/2014)... central nervous system disease that is caused by ... the embryonic phase. Many patients have varying degrees ... retardation. Such problems decrease the patients, functional independence ... Physical Medicine and Rehabilitation Education and Research Hospital, ... SB, using the Pediatric Evaluation of Disability Inventory ...
(Date:7/25/2014)... researchers have detected an unknown interaction between microorganisms and ... into a droplet of salt water and is left ... create biomineralogical biosaline 3D morphologically complex formations, where they ... revived. The discovery was made by chance with a ... Astrobiology journal and may help to find ...
(Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- The Geneva Healthcare ... cardiac devices, has cut emergency room wait times by ... Diego (UCSD) Medical Center, according to a recent study ... Emergency Departments are using the suite to access data ... or defibrillators. "Using Geneva,s technology platform we ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
(Date:7/25/2014)... The Little Gym of Houston will ... July 27 at Discovery Green in downtown Houston. The ... Pearland, Friendswood, Spring, The Woodlands, Sugarland-Missouri City, Kingwood, Bellaire ... “We’re thrilled to be attending and performing at the ... owns the Sugarland-Missouri City location. “We believe in the ...
(Date:7/25/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Ibuprofen and Oxcarbazepine Tablets . ... of Ibuprofen and one lot of Oxcarbazepine Tablets, by American ... packaging. Oxcarbazepine is used for the treatment of certain types ... reason for the recall is that Lot #142588, Expiration Date, ...
(Date:7/25/2014)... Ticket Down is a reliable source for cheap ... California Memorial Stadium. With the post-World Cup emotions still rolling ... the 2014 Guinness International Champions Cup have brought eight of ... representing La Liga, English Premier League, Serie A, and Superleague ... players from around the world to 12 American cities and ...
(Date:7/25/2014)... July 25, 2014 On July ... Nuanced Media client and the nation’s number one ... employee handbooks, announced their partnership with TransAct Merchant ... a registered ISO/MSP of Chase Paymentech Solutions, LLC, ... processing industry. Companies that are members of TransAct’s ...
(Date:7/25/2014)... Hastings and Hastings, a ... with regard to personal injury claims, announces free initial ... of legal services for those that have been injured ... or corporation. Free initial consultation services gives clients’ greater ... potential personal injury claim . It also offers ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3
Other TagsOther Tags